18 Results

People

  1. Davey
    Davey
  2. Hancock
    Hancock
  3. Moskowitz
    Moskowitz
  4. Horwitz
    Horwitz
  5. Galasso
    Galasso
  6. Ganesan
    Ganesan
  7. Noy
    Noy
  8. Kumar
    Kumar
  9. Dogan
    Dogan
  10. Zelenetz
    Zelenetz

Groups

  1. Advanced Practice Providers (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Hematologic Malignancies, Division of (18)
  5. Lymphoma (18)
  6. Population Sciences Research Program (17)
  7. Sloan Kettering Institute Postdocs (10)
  8. Survivorship Research (10)
  9. GSK Faculty (9)
  10. Human Oncology and Pathogenesis Program (9)
  1. "Center for Hematologic Malignancies"
  2. "Lymphoma"
  3. "Helen Hancock"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (2)
Groups
  1. Advanced Practice Providers (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Hematologic Malignancies, Division of (18)
  5. Lymphoma (18)
  6. Population Sciences Research Program (17)

More Groups

People
  1. Alison Moskowitz (18)
  2. Helen Hancock (18)
  3. Theresa Davey (18)
  4. Steven Horwitz (17)
  5. Natasha Galasso (14)
  6. Nivetha Ganesan (14)

More People

Years
  1. 2023 (5)
  2. 2022 (1)
  3. 2021 (4)
  4. 2020 (2)
  5. 2019 (4)
  6. 2018 (2)
Publications
  1. Blood (12)
  2. Hematological Oncology (4)
  3. Cancer Research (1)
  4. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (12)
  2. Wiley Blackwell (4)
  3. American Association for Cancer Research (1)
  4. American Society of Clinical Oncology (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save